Engineered Cellular Immunotherapies in Cancer and Beyond

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2022 Apr 20

PMID 35440724

Authors

Amanda V Finck

Tatiana Blanchard

Christopher P Roselle

Giulia Golinelli

Carl H June

Affiliations

Soon will be listed here.

Abstract

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.

Citing Articles

Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.

A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8 T cell fitness in solid tumours.

Pretto S, Yu Q, Bourdely P, Trusso Cafarello S, Van Acker H, Verelst J Nat Metab. 2025; .

PMID: 40065102 DOI: 10.1038/s42255-025-01233-w.

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.

Li C, Sharma S, Heczey A, Woods M, Steffin D, Louis C Nat Med. 2025; .

PMID: 39962287 DOI: 10.1038/s41591-025-03513-0.

Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture.

Li Y, Zhou K, Lee D, Zhu Y, Halladay T, Yu J Nat Protoc. 2025; .

PMID: 39825143 DOI: 10.1038/s41596-024-01077-w.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

References

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

Frangoul H, Altshuler D, Cappellini M, Chen Y, Domm J, Eustace B . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2020; 384(3):252-260. DOI: 10.1056/NEJMoa2031054. View

Elisseeff J, Badylak S, Boeke J . Immune and Genome Engineering as the Future of Transplantable Tissue. N Engl J Med. 2021; 385(26):2451-2462. PMC: 9009215. DOI: 10.1056/NEJMra1913421. View

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894. PMC: 11773457. DOI: 10.1016/S0140-6736(20)32334-5. View

Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A . Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007; 7(2):309-19. DOI: 10.1111/j.1600-6143.2006.01621.x. View

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

Beatty G, Gladney W . Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014; 21(4):687-92. PMC: 4334715. DOI: 10.1158/1078-0432.CCR-14-1860. View

CUDKOWICZ G, Stimpfling J . DEFICIENT GROWTH OF C57BL MARROW CELLS TRANSPLANTED IN F1 HYBRID MICE. ASSOCIATION WITH THE HISTOCOMPATIBILITY-2 LOCUS. Immunology. 1964; 7:291-306. PMC: 1423380. View

Murphy W, Kumar V, Bennett M . Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med. 1987; 166(5):1499-509. PMC: 2189655. DOI: 10.1084/jem.166.5.1499. View

10.

Kiessling R, Hochman P, Haller O, Shearer G, Wigzell H, CUDKOWICZ G . Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol. 1977; 7(9):655-63. DOI: 10.1002/eji.1830070915. View

11.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100. DOI: 10.1126/science.1068440. View

12.

Huntington N, Vosshenrich C, Di Santo J . Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007; 7(9):703-14. DOI: 10.1038/nri2154. View

13.

Raulet D . Bone Marrow Cell Rejection, MHC, NK Cells, and Missing Self Recognition: Ain't That Peculiar (with Apologies to Marvin Gaye). J Immunol. 2015; 195(7):2923-5. PMC: 5305116. DOI: 10.4049/jimmunol.1501804. View

14.

Liu W, Xiao X, Demirci G, Madsen J, Li X . Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J Immunol. 2012; 188(6):2703-11. PMC: 3298083. DOI: 10.4049/jimmunol.1102997. View

15.

Marino J, Paster J, Benichou G . Allorecognition by T Lymphocytes and Allograft Rejection. Front Immunol. 2016; 7:582. PMC: 5155009. DOI: 10.3389/fimmu.2016.00582. View

16.

Kanda Y, Takeuchi A, Ozawa M, Kurosawa Y, Kawamura T, Bogdanova D . Visualizing the Rapid and Dynamic Elimination of Allogeneic T Cells in Secondary Lymphoid Organs. J Immunol. 2018; 201(3):1062-1072. DOI: 10.4049/jimmunol.1700219. View

17.

Kitazawa Y, Ueta H, Sawanobori Y, Katakai T, Yoneyama H, Ueha S . Novel Targeting to XCR1 Dendritic Cells Using Allogeneic T Cells for Polytopical Antibody Responses in the Lymph Nodes. Front Immunol. 2019; 10:1195. PMC: 6548820. DOI: 10.3389/fimmu.2019.01195. View

18.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

19.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

20.

Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M . The allogeneic graft-versus-cancer effect. Br J Haematol. 2009; 147(5):614-33. DOI: 10.1111/j.1365-2141.2009.07886.x. View